Table 1.

Aurora kinases in cancer

AlterationCancer typeAurora kinaseCorrelationStudy
OverexpressionBreastAURKANATanaka et al. (51)
AURKAChromosomal instability, high grade, ER/PR negativityMiyoshi et al. (52)
AURKACentrosome anomalyHoque et al. (53)
AURKANuclear gradeRoyce et al. (54)
LungAURKANASmith et al. (26)
AURKAPoor differentiationXu et al. (55)
AURKBGenetic instabilitySmith et al. (26)
AURKBLymph node invasionVischioni et al. (56)
PancreasAURKANALi et al. (57)
ProstateAURKBGrade, proliferationChieffi et al. (58)
BladderAURKATumor recurrenceComperat et al. (59)
AURKATumor T stageFraizer et al. (60)
EsophagusAURKANATong et al. (61)
AURKANAYang et al. (62)
BrainAURKBGrade, outcomeAraki et al. (63)
AURKBSurvivalZeng et al. (64)
LiverAURKAGrade, stageJeng et al. (65)
Head/neckAURKANAZhao et al. (66)
AURKACentrosomal amplificationLi et al. (67)
AURKAProgression, survivalReiter et al. (68)
AURKBProliferation, histologic differentiation, and metastasisQi et al. (69)
ThyroidAURKBGrade, proliferationSorrentino et al. (70)
OvarianAURKAPosttreatment survivalLassmann et al. (71)
AURKASurvivalLanden et al. (72)
RenalAURKANo association detectedKurahashi et al. (73)
AmplificationBreastAURKABRCA2, TP53 mutationBodvarsdottir et al. (74)
AURKANASen et al. (75)
ColonAURKAGenetic instabilityNishida et al. (76)
AURKAOverexpressionBischoff et al. (17)
BrainAURKAOverexpressionReichardt et al. (77)
AURKANAKlein et al. (78)
AURKASurvivalNeben et al. (79)
BladderAURKAAneuploidy, grade, outcomeSen et al. (80)
Head/neckAURKANATatsuka et al. (81)
EndometriumAURKANAMoreno-Bueno et al. (82)
PolymorphismsColonAURKACancer risk (F31I)Chen et al. (83)
AURKACancer risk (F31I)Hienonen et al. (84)
AURKAAneuploidy (F31I)Ewart-Toland et al. (85)
BreastAURKACancer risk (F31I)Lo et al. (86)
AURKACancer risk (F31I)Vidarsdottir et al. (87)
AURKACancer risk (F31I)Cox et al. (88)
AURKBCancer risk (S295S)Tchatchou et al. (89)
EsophagusAURKACancer risk (F31I, V57I)Kimura et al. (90)
LungAURKAReduced cancer risk (F31I)Gu et al. (91)
GastricAURKARisk of disease progression (V57I)Ju et al. (92)
MultipleAURKACancer risk (F31I)Ewart-Toland et al. (93)
  • Abbreviations: NA, not addressed; F, phenylalanine; I, isoleucine; S, serine; V, valine; ER, estrogen receptor; PR, progesterone receptor.